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Table. 1-Year Cardiac Events for the Overall Population and Subsets of the ION
U.S. Post-Approval Registry
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All ION Registry
patients
(N¼1111)
9.4% (97/1028) 2.0% (21/1028) 3.0% (31/1028) 6.8% (70/1028) 2.1% (22/1028)
Combined Subsets From the ION and TE-PROVE Registries
PERSEUS-like
patients
(n¼622)
4.9% (25/594) 0.7% (4/594) 1.2% (7/594) 4.0% (24/594) 1.2% (7/594)
Medically
treated diabetes
(n¼635)
10.3% (61/594) 2.2% (13/594) 2.2% (13/594) 8.4% (50/594) 1.7% (10/594)
Insulin-treated
(n¼247)
11.9% (27/226) 3.1% (7/226) 1.3% (3/226) 10.2% (23/226) 0.9% (2/226)
Lesion Length
28mm
(n¼477)
8.6% (39/452) 1.1% (5/452) 2.9% (13/452) 6.6% (30/452) 2.4% (11/452)
Reference
vessel2.5mm
(n¼610)
9.7% (56/576) 1.9% (11/576) 2.4% (14/576) 7.6% (44/576) 2.1% (12/576)
Bifurcation
Lesions
(n¼281)
9.9% (27/272) 1.5% (4/272) 2.6% (7/272) 6.6% (18/272) 0.7% (2/272)
Total Occlusion
(n¼246)
8.1% (19/235) 0.4% (1/235) 3.4% (8/235) 6.4% (15/235) 2.1% (5/235)
Overlapping
Stents
(n¼369)
9.9% (35/353) 0.6% (2/353) 4.8% (17/353) 7.1% (25/353) 2.3% (8/353)
Unstable
Angina
(n¼797)
8.1% (60/742) 1.5% (11/742) 2.3% (17/742) 6.1% (45/742) 1.6% (12/742)
MACE¼major adverse cardiac events (deﬁned as CD, MI, and TVR); CD¼cardiac death;
MI¼myocardial infarction; TVR¼target vessel revascularization; ARC ST¼Academic Research
Consortium deﬁnite/probable stent thrombosis.
By prespeciﬁcation, subset analyses combine the ION and TE-PROVE populations. Binary
rates.
aION protocol deﬁnition
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Background: The TE-PROVE post-market registry is evaluating clinical outcomes
for patients receiving the third-generation, paclitaxel-eluting, platinum chromium
TAXUS Element stent (Boston Scientiﬁc, Natick, MA) over 5 years in a real-world
setting. This is the ﬁrst report of results from this large multicenter registry.
Methods: This was a prospective, open-label, multicenter observational 'all-comers'
study that included 1014 patients at 37 sites in Europe. Follow-up was at 30 days, 6
months, and 1 year, and will continue annually through 5 years. The primary endpoint
was the overall and TAXUS Element stent-related target vessel failure rate (TVF,
deﬁned as cardiac death, and target vessel-related myocardial infarction [MI] and
reintervention [TVR]) at 1 year post-implantation. Secondary endpoints included the
components of TVF, all-cause mortality, and ARC deﬁnite/probable stent thrombosis.
Results: Among 1014 enrolled patients, 1-year clinical follow-up or death occurred in
97.3% (987/1014) of patients. Patients were 75.0% male (760/1014), mean age was
65.110.8 years, 25.5% had medically treated diabetes (259/1014), and 10.7% (109/
1014) were treated for STEMI. At baseline, mean lesion length among 1299 treated
lesions was 19.812.0 mm and mean reference vessel diameter was 3.10.5 mm.
At 1 year, the rate of TVF (primary endpoint) was 6.0% (59/987), of which 3.7%
(37/987) was considered related to the study stent. Cardiac death was 0.7% (7/987),
target vessel-related MI was 1.1% (11/987), and TVR was 4.7% (46/987). All-cause
death occurred in 1.2% (12/987) patients and ARC deﬁnite/probable ST was 0.5% (5/
987). Additional outcomes for subsets, including small vessels, long lesions, and
diabetes, will be available at the meeting.
Conclusions: The primary endpoint results from the TE-PROVE registry demonstrate
good performance and safety for the TAXUS Element paclitaxel-eluting stent at 1 year
in everyday clinical practice.
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Background: There are limited data for comparing the safety and efﬁcacy of ever-
olimus-eluting stent (EES) versus zotarolimus-eluting stents (ZES-R) for long-term
follow-up. This study evaluated the safety and efﬁcacy of these two stents in real-
world practice for 3-year of follow-up.
Methods: 926 patients who treated with EES (Xience V, Abbott Vascular, USA; n
¼459) and ZES-R (Endeavor Resolute, Medtronic Cardiovascular, USA; n ¼ 467)
were analyzed using single center registry from 2008 to 2010 after excluding the
patients with cardiogenic shock at admission and the patients with in-hospital
mortality for reducing the potential selection bias. Primary endpoint was a composite
of any death, any myocardial infarction, and target vessel-revascularization at 3-year
of follow-up.
Results: ZES-R group was younger (64.5  10.8 year vs. 66.0  10.2 year, p ¼
0.033) then EES group but other baseline characteristics and laboratory ﬁndings were
similar between two groups. EES was more used for left main lesion (9.8% vs. 3.9%, p
< 0.001) but ZES-R was more used for right coronary artery (30.3% vs. 41.3%, p <
0.001). Although implanted number of stent was not different between two groups,
EES was larger in diameter (3.11  0.42 mm vs. 3.06  0.40 mm, p ¼ 0.026) and
shorter in length (40.2  24.7 mm vs. 45.3  25.7 mm, p ¼ 0.002) compared with
ZES-R. Discharge medication was not different between two groups. During 3-year of
follow-up (920  206 days in EES group vs. 900  216 days in ZES-R group, p ¼
0.152), primary endpoint was not different between two groups (14.4% in EES group
vs. 16.3% in ZES-R group, p ¼ 0.466). Stent thrombosis was similar between two
groups (0.9% vs. 1.3%, p ¼ 0.387).
Conclusions: In this real-world registry with unrestricted use of EES and ZES-R, two
new generation drug-eluting stent showed comparable safety and efﬁcacy during long-
term follow-up.B58 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-180
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Background: The ION Registry assessed clinical outcomes for the thin-strut, ION
(TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System
(Boston Scientiﬁc, Natick, MA) in unselected patients. This is the ﬁrst report of results
from this large multicenter registry.
Methods: This prospective, open-label registry enrolled the ﬁrst 1120 consenting
patients treated with the ION stent for any indication at 40 clinical sites in the United
States. Follow-up was at discharge, 30 and 180 days, and annually to 5 years. The
primary endpoint was the 1-year rate of cardiac death or MI in PERSEUS-like patients
(JACC 2010;56:264–71). Per protocol, the primary endpoint result from the ION
registry was also combined with the European post-approval registry (TE-PROVE),
which enrolled 306 PERSEUS-like patients, and the PERSEUS WH/SV populations
(N¼1166).
Results: 1111 patients received a study stent, 316 were PERSEUS-like, and 1-year
follow-up was 92.1% (1023/1111). Most patients were male (70.3%, 781/1111) with
a mean age 64.111.0 years. At 1 year, the primary endpoint of CD/MI occurred in
2.1% (6/292) of PERSEUS-like patients in ION and 2.3% (40/1729) patients in the
combined analysis. The upper 1-sided 95% CI for the combined analysis was 2.9%,
which was signiﬁcantly less than the prespeciﬁed performance goal of 7.6%
(P<0.001). Secondary endpoints and subsets are given in the Table.Conclusions: The 1-year results of the ION U.S. Post-Approval Study conﬁrm the
safety and effectiveness of the ION stent for the treatment of coronary artery disease in
everyday clinical practice.j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
